Cardiovascular disease remains the leading global cause of mortality. High-frequency ultrasound is the irreplaceable, non-invasive in vivo gold standard for cardiac assessment. Efficient, automated systems with low learning curves are highly sought after by high-throughput drug screening labs.

Oncology represents the largest and most heavily funded segment in preclinical imaging. Driven by the boom in immuno-oncology and targeted drug discovery, there is a massive market demand for high-definition ultrasound capable of longitudinal, long-term tracking in living mice.

The democratization of gene-editing technologies (e.g., CRISPR) has generated a vast need for phenotypic validation. Ultrasound-guided micro-injection significantly improves embryo survival rates and strictly aligns with the 3R Principles (Reduction and Refinement), making it an absolute necessity for cutting-edge academic institutes.